Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.43 |
| ▸ | PARN | O95453 | 1/20 | 0.40 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6378435 | 0.93 | MAPK14 (0.55) | MAPK14KCNH2MCHR1PFKFB3NR2E3 | |
| SCHEMBL6370522 | 0.83 | MAPK14 (0.58) | MAPK14PFKFB3NR2E3 | |
| SCHEMBL6291906 | 0.81 | MAPK14 (0.65) | MAPK14PFKFB3NR2E3 | |
| SCHEMBL6371703 | 0.76 | MAPK14 (0.59) | MAPK14PFKFB3NR2E3 | |
| SCHEMBL6369871 | 0.73 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL6370740 | 0.70 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL27692027 | 0.70 | NR2E3 (0.45) | MAPK14NR2E3 | |
| SCHEMBL6232624 | 0.69 | MAPK14 (0.67) | MAPK14PFKFB3NR2E3 | |
| SCHEMBL6371347 | 0.67 | MAPK14 (0.89) | MAPK14 | |
| SCHEMBL6265589 | 0.66 | MAPK14 (0.62) | MAPK14NR2E3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256122-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20050020594-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | disclosed |
| US-20040142932-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142932-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | MAPK14 29/4885KCNH2 3645/4885MCHR1 4315/4885 |
| US-20050020594-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | MAPK14 34/4885KCNH2 3836/4885MCHR1 4425/4885 |
| US-20050256122-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | MAPK14 34/4885KCNH2 3836/4885MCHR1 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.